AbCellera Biologics (ABCL) Equity Average (2021 - 2025)
Historic Equity Average for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2025 value amounting to $985.6 million.
- AbCellera Biologics' Equity Average fell 995.62% to $985.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $985.6 million, marking a year-over-year decrease of 995.62%. This contributed to the annual value of $1.1 billion for FY2024, which is 742.76% down from last year.
- Latest data reveals that AbCellera Biologics reported Equity Average of $985.6 million as of Q3 2025, which was down 995.62% from $1.0 billion recorded in Q2 2025.
- AbCellera Biologics' Equity Average's 5-year high stood at $1.2 billion during Q4 2022, with a 5-year trough of $893.8 million in Q1 2021.
- Its 5-year average for Equity Average is $1.1 billion, with a median of $1.1 billion in 2022.
- In the last 5 years, AbCellera Biologics' Equity Average surged by 2821.09% in 2022 and then plummeted by 995.62% in 2025.
- Quarter analysis of 5 years shows AbCellera Biologics' Equity Average stood at $989.6 million in 2021, then increased by 25.48% to $1.2 billion in 2022, then dropped by 5.97% to $1.2 billion in 2023, then dropped by 8.6% to $1.1 billion in 2024, then decreased by 7.64% to $985.6 million in 2025.
- Its Equity Average stands at $985.6 million for Q3 2025, versus $1.0 billion for Q2 2025 and $1.0 billion for Q1 2025.